Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8
mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver
disease/non-alcoholic steatohepatitis (NAFLD/NASH patients) with hypertension